Canine Bone Cancer Vaccine Hints at a Human Version



More than 10,000 cases of bone cancer in dogs occur in the United States each year. But the disease is not common in humans, with only 800 to 900 cases a year. About half of those cases occur in children and teens.

The new vaccine is made from a dog's own tumor and targets specific cancer cells and eliminates the need for chemotherapy, which can cause toxic side effects, according to the University of Missouri researchers.

"A vaccine is made out of the dog's own tumor for the dog's immune system to recognize," explained Jeffrey Bryan, a professor of oncology at the College of Veterinary Medicine. He is also director of the university's Comparative Oncology Radiobiology and Epigenetics Laboratory.

Dogs that received the vaccine had more than 400 days of remission, compared with about 270 days for dogs that received chemotherapy in a separate study by the U.S. National Cancer Institute.

"The dogs received no chemotherapy and received only immunotherapy after their surgery. It's the first time that dogs with osteosarcoma [bone cancer] have experienced prolonged survival without receiving chemotherapy, which is really exciting," Bryan said in a university news release.

This treatment uses a dog's own lymphocytes, which "are immune cells that recognize where pathogens are hiding in the body and then kill the cells harboring those pathogens," Bryan said.

"After we remove the tumor, we create a vaccine using the dog's tumor cells to stimulate anti-tumor lymphocytes," that are then transfused into the dog, he explained.

"These cells are activated and essentially really angry at whatever they are supposed to attack. When put back into the body, they should identify and destroy tumor cells. Ideally, this immune response would destroy every last tumor cell," Bryan said.

However, animal studies do not always pan out in humans.

The study was presented recently at the Veterinary Cancer Society Annual Conference in Louisville, Ky. Such research is considered preliminary until published in a peer-reviewed journal.

The team plans to continue its research with the goal of eventually conducting clinical trials of the vaccine therapy to treat bone cancer and other types of cancers in people.

More information

The U.S. National Cancer Institute has more on bone cancer.


Source: https://www.drugs.com/news/canine-bone-cancer-vaccine-hints-human-version-80223.html?utm_source=ddc&utm_medium=rss&utm_campaign=Canine+Bone+Cancer+Vaccine+Hints+at+a+Human+Version

Canine Bone Cancer Vaccine Hints at a Human Version



Dogs will be randomized to why Do More and More Americans Use Medical Marijuana? either cotc021 or cotc022 at the start of therapy, which will determine the treatment prescribed. It's the first time that dogs with osteosarcoma bone cancer have experienced prolonged survival without receiving chemotherapy, which is really exciting Bryan said in a university news release. Most dogs undergo amputation and chemotherapy for bone cancer with median survival of about 1 year due to metastatic spread to the lungs. Benefits: Benefits of standard therapy include removal of the painful cancerous tumor in your dogs bone and delay of spread of cancer by providing chemotherapy with carboplatin. The standard of care for humans and dogs with osteosarcoma is surgery followed by chemotherapy. Treatment for...

Is possible for an additional fee Exclusion criteria: Patients with 1 month expected survival, concurrent severe co-morbidities. Oral rapamycin to start within 7 days of week 15 visit- Monday - Thursday administration. Ideally, this immune response would destroy every last tumor cell Bryan said. Dogs must weigh. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Dogs will undergo preliminary staging aHA News: Post-Stroke Depression Common Among Black, Hispanic Survivors tests including initial consultation, physical examination, lab work, thoracic radiographs, and tumor biopsy/immunohistochemistry to determine trial eligibility.